Evommune, Inc.
NYSE: EVMN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Luis C. Pena
- Employees
- 45
- Headquarters
- Palo Alto, United States
- IPO year
- 2025
- Market cap
- $333.7M
- Website
- https://www.evommune.com
Loading EVMN…
Loading profile data…Frequently asked questions about EVMN
What does Evommune, Inc. (EVMN) do?
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic derma...
Where does EVMN trade?
Evommune, Inc. (EVMN) trades on the New York Stock Exchange.
What sector is EVMN in?
Evommune, Inc. (EVMN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Evommune, Inc.?
Luis C. Pena is the chief executive officer of Evommune, Inc. (EVMN).
Where is Evommune, Inc. headquartered?
Evommune, Inc. is headquartered in United States.
Does EVMN pay a dividend?
Evommune, Inc. (EVMN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EVMN go public?
Evommune, Inc. (EVMN) completed its initial public offering in 2025.